Results 131 to 140 of about 176,622 (333)

Full Issue: Volume 13, Issue 1 - Winter 2018 [PDF]

, 2018
Full Issue: Volume 13, Issue 1 - Winter ...

core   +1 more source

Pharmacologic pitfalls in heart failure: A guide to drugs that may cause or exacerbate heart failure. A European Journal of Heart Failure expert consensus document

European Journal of Heart Failure, EarlyView.
Main categories of harmful drugs in heart failure. CCB, calcium channel blocker; DPP4i, dipeptidyl peptidase‐4 inhibitor; HER2‐TT, human epidermal growth factor receptor 2‐targeted therapy; NSAID, non‐steroidal anti‐inflammatory drug; TKI, tyrosine kinase inhibitor; TZD, thiazolidinedione; VEGF Inh, vascular endothelial growth factor inhibitor.
Amr Abdin, Johann Bauersachs, Magdy Abdelhamid, Suleman Aktaa, Hussam Al Ghorani, Antonio Bayes‐Genis, Jan Biegus, Michael Böhm, Javed Butler, Nicolas Girerd, Marco Metra, Wilfried Mullens, Hadi Skouri, Muthiah Vaduganathan, Seif El Hadidi, Giuseppe M.C. Rosano, Gianluigi Savarese   +16 more
wiley   +1 more source

Bevacizumab for the Treatment of Recurrent Glioblastoma

Clinical Medicine Insights: Oncology, 2011
Despite advances in upfront therapy, the prognosis in the great majority of patients with glioblastoma (GBM) is poor as almost all recur and result in disease-related death.
Marc C. Chamberlain
doaj   +1 more source

VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528 [PDF]

, 2012
Oliver Gautschi, Anne‐Marie C. Dingemans, Susanne Crowe, Solange Peters, Heinrich Röder, Julia Grigorieva, Joanna Roder, Francesco Zappa, Miklos Pless, Martin Brutsche, Florent Baty, Lukas Bubendorf, Shu‐Fang Hsu Schmitz, Kyung-Jae Na, David P. Carbone, Rolf A. Stahel, Egbert F. Smit   +16 more
openalex   +1 more source

Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases [PDF]

, 2015
Émilie Le Rhun, Sophie Taillibert, Thomas Boulanger, Fahed Zaïri, Jacques Bonneterre, Marc C. Chamberlain   +5 more
openalex   +1 more source

A novel method of screening combinations of angiostatics identifies bevacizumab and temsirolimus as synergistic inhibitors of glioma-induced angiogenesis

, 2021
Michael I. Dorrell, Heidi R. Kast-Woelbern, Ryan T. Botts, Stephen Bravo, Jacob R. Tremblay, Sarah Giles, Jessica F. Wada, MaryAnn Alexander, Eric Alejandro García, Gabriel Villegas, Caylor B. Booth, Kaitlyn J. Purington, Haylie M. Everett, Erik N. Siles, Michael Wheelock, Jordan A. Silva, Bridget M. Fortin, Connor A. Lowey, Allison L. Hale, Troy L. Kurz, Jack C. Rusing, Dawn M. Goral, Paul Thompson, Alec M. Johnson, Daniel J. Elson, Roujih Tadros, Charisa E. Gillette, Carley Coopwood, Amy L. Rausch, Jeffrey M. Snowbarger   +29 more
openalex   +2 more sources

The role of cytokines in ovarian cancer drug resistance

International Journal of Cancer, EarlyView.
Abstract Ovarian cancer is the leading cause of death among women diagnosed with female reproductive system cancers. While significant advances have been made in treating various types of cancer, progress in ovarian cancer treatment over the past 20 years has been minimal, and the treatment course of ovarian cancer is not linear. Although many patients
Lu Wang, Yunxia Zang, Rebeka Dejenie, Junyuan Bing, Shixia Dong, Yanfei Zhang, Yi Zhu, Jingjing Li   +7 more
wiley   +1 more source

Novel therapeutic strategy targeting STMN1 using chlorambucil‐conjugated pyrrole–imidazole polyamide in small cell lung cancer

International Journal of Cancer, EarlyView.
What's New? Small cell lung cancer (SCLC) is aggressive and difficult to treat but exhibits high levels of stathmin 1 (STMN1), a candidate therapeutic target. In this study, the authors synthesized a chlorambucil (Chb)‐conjugated pyrrole–imidazole polyamide (PIP) compound targeting the STMN1 promoter and DNA sequences and evaluated its efficacy in ...
Ryohei Yoshikawa, Takayoshi Watanabe, Yoichi Ohtaki, Toshikazu Bando, Hiroshi Sugiyama, Takuya Araki, Hideaki Yashima, Bilguun Erkhem‐Ochir, Haruka Okami, Gendensuren Dorjkhorloo, Ikuma Shioi, Toshiteru Nagashima, Natsuko Kawatani, Tomohiro Yazawa, Eiji Narusawa, Takayuki Kosaka, Osamu Kawashima, Mitsuhiro Kamiyoshihara, John D. Minna, Luc Girard, Ken Shirabe, Hiroki Nagase, Kimihiro Shimizu, Takehiko Yokobori   +23 more
wiley   +1 more source

Head‐to‐head comparison of TKI and CPI first‐line treatment strategies in advanced renal cell carcinoma—Real‐world data from the German research platform CARAT

International Journal of Cancer, EarlyView.
What's New? The current standard of care for locally advanced or metastatic renal cell carcinoma (aRCC) is either a combination of two immune checkpoint inhibitors (CPI) or a CPI plus a tyrosine kinase inhibitor (TKI). Here, the authors simulate a head‐to‐head trial comparing the real‐world effectiveness of these combination therapies with TKI ...
Peter J. Goebell, Martin Bögemann, Arnd Nusch, Viktor Grünwald, Lothar Müller, Eyck von der Heyde, Uwe M. Martens, Carolin Lennartz, Michaela Koska, Karin Potthoff, Anja Kaiser‐Osterhues, Carsten Grüllich, Michael Staehler, Martina Jänicke, Dominik Marschner, the CARAT Registry Group   +15 more
wiley   +1 more source

Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients

International Journal of Cancer, EarlyView.
What's New? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman, Nahal Masrour, Naina Patel, Anna M. Piskorz, Robert Brown, James D. Brenton, Iain A. McNeish, James M. Flanagan   +7 more
wiley   +1 more source